Navigation Links
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Date:1/14/2009

rt an optimal therapeutic dose level of 50 kBq/kg as selected for use in the global phase III ALSYMPCA trial (see below for further details).

Furthermore, the successful completion of the phase II program also supports Algeta's strategy for targeting Alpharadin at patients with metastatic HRPC who are unsuitable or who have failed docetaxel chemotherapy and for first-line use in combination with docetaxel. A combination study is in preparation, which if successful will enable Algeta to market Alpharadin, either alone or in combination with docetaxel, to approximately 85% of the global HRPC market.

Algeta's President and CEO, Dr. Thomas Ramdahl, said: "The completion of the phase II program is an important milestone for Algeta that gives us great confidence in the potential of Alpharadin as a new, safe and effective treatment for metastatic prostate cancer. The program has demonstrated not only that Alpharadin can improve patient quality of life by successfully treating the painful and debilitating bone metastases arising from the primary cancer, but also that it has a proven survival benefit for patients. We believe there is not a single cancer therapeutic available today offering these patients such clinical benefits, let alone one which is so readily tolerated. We remain confident that the phase III clinical program will confirm these impressive results and support a strong case for regulatory approval in due course."

Dr Chris Parker, a prostate cancer specialist based at the Institute of Cancer Research and the Royal Marsden Hospital in Sutton, UK, and the study's principal investigator, said: "The clinical results generated so far for Alpharadin in treating metastatic prostate cancer are highly encouraging and offer patients the possibility of an effective treatment that both prolongs life while also maintaining quality of life. In addition, the results announced today further emphasize the remark
'/>"/>

SOURCE Algeta
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
2. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
7. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ... today that the Company will present at the Stifel Dental ... the Le Parker Meridian hotel, 119 W. 56 th ... presentation is scheduled to begin at 2:15 p.m. Eastern Time ... Heska Corporation (NASDAQ: HSKA - News) sells ...
(Date:5/22/2013)... Conn. , May 22, 2013 /PRNewswire-iReach/ -- ... stay aligned with the latest trends and events, ... that can predict where an industry is headed ... evolve. (Photo: http://photos.prnewswire.com/prnh/20130522/CG19099 ) ... partnership with market research publisher GlobalData, offer decision ...
(Date:5/22/2013)... May 22, 2013   Accuray Incorporated (Nasdaq: ... is scheduled to present at the 2013 Jefferies Global ... on Thursday, June 6, 2013 at 1:30 p.m. EDT/10:30 ... presentation will be available online from the Investor Relations ... The webcast replay of the presentation will begin ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4
... 15 Researchers at the Barbara,Ann Karmanos Cancer ... developed a HER2 DNA vaccine that has shown ... The study was reported in the September 15 ... Association for Cancer,Research., ( http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELO ,GO), ...
... women each year than all cancers combined. Although ... patients, the,unique risk factors and symptoms of female ... disease particularly challenging., Data from the WOMEN ... in WomeN presented today at the American Society ...
Cached Medicine Technology:DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers 2What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study 2
(Date:5/23/2013)... children and adolescents with seizures involving the temporal ... problems and psychiatric illness, especially depression. Findings published ... Wiley on behalf of the International League Against ... evaluation for pediatric epilepsy patientsparticularly for those who ... epilepsy surgery. , Current medical evidence indicates ...
(Date:5/23/2013)... 23, 2013 CareAnyware , ... health and hospice software solutions, and Cornell University ... showed significant reductions in rehospitalization rates for clinically ... Carepath protocol incorporated into CareAnyware’s EMR system. Based ... which included a 39% reduction in rehospitalization rates ...
(Date:5/23/2013)... Lotus Valve, a second-generation transcatheter aortic valve implantation ... the first 60 patients in results from REPRISE ... device performance and low mortality at 30 days., ... but there are opportunities for improvement," explained lead ... and Professor of Medicine, Monash University, Melbourne, Australia. ...
(Date:5/23/2013)... Diego, CA (PRWEB) May 23, 2013 ... Medicus Ltd. (ASX: PME), announced today that they ... available on the Apple App Store*. When used in ... Platform, Visage Ease provides authorized healthcare providers simple mobile ... Touch iOS devices. , In addition to numerous enhancements ...
(Date:5/23/2013)... 2013 Registered Dietitian and Founder of ... today on Tatalou.com offering helpful tips for travelers who ... titled “ How to Stay Healthy While Traveling ,” ... sanitizer, when it’s safe to drink the water when ... importance of staying hydrated and how taking health supplements ...
Breaking Medicine News(10 mins):Health News:Depression common among children with temporal lobe epilepsy 2Health News:CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients 2Health News:CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients 3Health News:Second-generation TAVI device -- Lotus Valve -- shows good performance in REPRISE II 2Health News:Mobile Imaging Access Leaps Ahead with Visage Ease 2Health News:Mobile Imaging Access Leaps Ahead with Visage Ease 3Health News:How to Stay Healthy While Traveling 2
... and Rainbow,Kitchen Community Services announced today that they ... Against Hunger" on Saturday, April 26, 2008.,The event ... and services, and raises public awareness about the,benefits ... participants can either walk or ride bicycles,along the ...
... April 24 Prime Therapeutics (Prime), a,thought leader ... RPh, has joined the organization as Vice President ... Pharmacy Trade Relations, Wan will focus on,developing and ... Prime,s efforts in the development of strategic pharmacy,contracts ...
... Frankfurt: I7VF), INVERNESS, Scotland, April 24 /PRNewswire-FirstCall/ - ... sheet restructuring,leaving it free of all loan note indebtedness, ... to enable it to move forward. The Company has,been ... 2005., Medical Diagnostic Innovations Ltd, a UK investment ...
... (Nasdaq: STAA ) today announced that it will ... 2008 on Tuesday, May 6, 2008,after the market close. ... Tuesday, May 6, 2008 at 5:00 p.m. Eastern Time ... The dial-in number for,the conference call is 866-250-3615 for ...
... 24 The Quigley,Corporation (Nasdaq: QGLY ) today ... the first quarter ended March 31, 2008,compared to $6.1 ... The first quarter of 2008 reflects a net sales ... compared to the first quarter,of 2007. The change during ...
... ) announced that it will release first quarter 2008,financial results on Thursday, ... The Company will host a conference call to discuss the first ... First Quarter 2008 Earnings Conference Call, ... Thursday, May 1, 2008 at 5:00 p.m. Eastern Time, Dial-in: ...
Cached Medicine News:Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 2Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 3Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 2Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 3Health News:STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 5
The ArthroPasser easily passes any type of suture through tissue and its smooth jaw assists in eliminating,suture fraying....
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 right angled suture passer....
45 right angled suture passer....
Medicine Products: